Table 2 A compilation of the NCs employed in clinical trials (reused from Kaushik et al., 2022, distributed under Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium. http://creativecommons.org/licenses/by/4.0/) [170]
Products | Drug | Nanocarrier | Application |
|---|---|---|---|
Lipoplatin | Cisplatin | Liposomal | Non-small cell lung cancer |
Onco-TCS | Vincristine | Â | Relapsed non-Hodgkin lymphoma |
OSI-211 | Lurotecan | Â | Head, neck, and ovarian cancer |
SPI-077 | Cisplatin | Â | Head, lung, and neck cancer |
PNU166945 | Paclitaxel | Polymeric | Solid tumours |
XMT-1001 | Camptothecin | Â | Gastric cancer and lung cancer |
PEG-SN38 | Irinotecan derivate | Â | Solid tumours and breast cancer |
Livatag | Doxorubicin | Â | Liver cancer |
NKTR-105 | Docetaxel | Â | Solid tumours and ovarian cancer |
Paclical | Paclitaxel | Â | Breast, lung, and ovarian cancer |
PEG-docetaxel | Docetaxel | Â | Solid tumours |